Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 8/20 | 0.46 |
| ▸ | KDM5A | P29375 | 8/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 8/20 | 0.46 |
| ▸ | KDM6B | O15054 | 4/20 | 0.46 |
| ▸ | KDM5C | P41229 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.46 |
| ▸ | KDM3A | Q9Y4C1 | 3/20 | 0.46 |
| ▸ | KDM4A | O75164 | 3/20 | 0.46 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TET3 | O43151 | 1/20 | 0.46 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ASPH | Q12797 | 1/20 | 0.46 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.46 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.46 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.46 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.46 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5364217 | 0.85 | JMJD6 (0.51) | KDM4CKDM5AKDM5BKDM5CJMJD6 | |
| SCHEMBL16054683 | 0.79 | KDM4C (0.50) | KDM4CKDM5AKDM5BKDM6BKDM5C | |
| SCHEMBL25933767 | 0.78 | KDM5B (0.49) | KDM4CKDM5AKDM5BKDM6BKDM5C | |
| SCHEMBL1759894 | 0.76 | KDM4C (0.55) | KDM4CKDM5AKDM5BKDM6BKDM5C | |
| SCHEMBL14836839 | 0.76 | KDM4C (0.47) | KDM4CKDM5AKDM5BKDM6BKDM5C | |
| SCHEMBL19705976 | 0.75 | KDM4C (0.46) | KDM4CKDM5AKDM5BKDM6BKDM5C | |
| SCHEMBL17545205 | 0.75 | GABRP (0.56) | KDM4CKDM5AKDM5BKDM6BKDM5C | |
| SCHEMBL25933765 | 0.75 | KDM4C (0.53) | KDM4CKDM5AKDM5BKDM6BKDM5C | |
| SCHEMBL23583774 | 0.74 | KDM4C (0.57) | KDM4CKDM5AKDM5BKDM6BKDM5C | |
| SCHEMBL1992514 | 0.73 | MAPT (0.57) | KDM4CKDM5AKDM5BKDM6BKDM5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259157-B2 | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists | MERCK & CO., INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-7259157-B2 | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists | MERCK & CO., INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-7259157-B2 | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists | MERCK & CO., INC. (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1390034-A4 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040204341-A1 | Nr2b receptor antagonists for the treatment or prevention of migraines | ALLEN CHRISTOPHER (US) | 2004-10-14 | — | — | US | disclosed |
| EP-1399160-A4 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | MERCK & CO INC (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-1399160-A2 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | Merck & Co., Inc. (US) | 2004-03-24 | — | — | EP | disclosed |
| EP-1390034-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030119811-A1 | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists | MERCK SHARP & DOHME CORP. | 2003-06-26 | — | — | US | disclosed |
| WO-2002100352-A2 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | MERCK & CO., INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002080928-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204341-A1 | Nr2b receptor antagonists for the treatment or prevention of migraines | HTR1B, HTR2B, HTR1A | KDM4C 4014/4885KDM5A 2142/4885KDM5B 1523/4885 |
| US-20030119811-A1 | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists | GRIN1, GRIN2B, GRIN2A | KDM4C 4316/4885KDM5A 3207/4885KDM5B 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.